PPARγ Cancer Research Results

PPARγ, Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG): Click to Expand ⟱
Source:
Type:
Peroxisome proliferator-activated receptor gamma (PPAR-γ) is a type of nuclear receptor that plays a crucial role in regulating various biological processes, including glucose metabolism, lipid metabolism, and inflammation. It is primarily expressed in adipose tissue, but it is also found in other tissues, including the colon, breast, and prostate.
PPAR-γ has been shown to have both tumor-suppressive and tumor-promoting effects, depending on the type of cancer and the context. In some cancers, activation of PPAR-γ can inhibit cell proliferation and induce apoptosis, while in others, it may promote tumor growth.
PPARγ
– Plays a central role in adipogenesis, lipid storage, and insulin sensitivity.
– Widely expressed in adipose tissue, but also present in colon, breast, and immune cells.
– In addition to metabolic functions, PPARγ regulates cell differentiation, apoptosis, and has anti-inflammatory effects.
– Ligand binding (such as endogenous fatty acids or synthetic agonists like thiazolidinediones) alters transcriptional programs impacting cell cycle and survival.

– In many cases, PPARγ is expressed in tumor cells, and its activation has been linked to induction of differentiation and growth arrest.
– However, expression levels can differ based on tumor subtype, with some studies reporting elevated levels while others note reductions in aggressive tumors.
– Crosstalk with other signaling pathways (e.g., Wnt/β-catenin, MAPK) can alter PPARγ's net effect in cancer cells.
Scientific Papers found: Click to Expand⟱
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2/PTGS2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,
3383- ART/DHA,    Dihydroartemisinin: A Potential Natural Anticancer Drug
- Review, Var, NA
TumCP↓, Apoptosis↑, TumMeta↓, angioG↓, TumAuto↑, ER Stress↑, ROS↑, Ca+2↑, p38↑, HSP70/HSPA5↓, PPARγ↑, GLUT1↓, Glycolysis↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, lactateProd↓, GlucoseCon↓, EMT↓, Slug↓, Zeb1↓, ZEB2↓, Twist↓, Snail?, CAFs/TAFs↓, TGF-β↓, p‑STAT3↓, M2 MC↓, uPA↓, HH↓, AXL↓, VEGFR2/KDR/Flk1↓, JNK↑, Beclin-1/ATG6↑, GRP78/BiP↑, eff↑, eff↑, eff↑, eff↑, eff↑, eff↑, IL4↓, DR5↑, Cyt‑c↑, Fas↑, FADD↑, cl‑PARP↑, cycE/CCNE↓, CDK2↓, CDK4↓, Mcl-1↓, Ki-67↓, Bcl-2↓, CDK6↓, VEGF↓, COX2/PTGS2↓, MMP9↓,
2615- Ba,    The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
- Review, Var, NA
*AntiCan↓, *Inflam↓, TumCP↓, NF-kB↓, PPARγ↑, TumCCA↑, JAK2↓, STAT3↓, TumCMig↓, Glycolysis↓, MMP2↓, MMP9↓, selectivity↑, VEGF↓, Hif1a↓, cMyc↓, ChemoSen↑, ROS↑, p‑mTOR↓, PTEN↑,
6504- BCP,    β-Caryophyllene Induces PPARγ-Mediated Apoptosis and Enhances the Radiosensitivity in Colorectal Cancer Cells
- in-vitro, CRC, CT26 - in-vitro, CRC, HCT116
RadioS↑, TumCCA↑, γH2AX↑, DNAdam↑, p‑Akt↓, cycD1/CCND1↓, PPARγ↑, Bax:Bcl2↑, Casp3↑, Apoptosis↑,
1082- CAR,    Carvacrol, a component of thyme oil, activates PPARα and γ and suppresses COX-2 expression
- in-vitro, lymphoma, U937
COX2/PTGS2↓, PPARα↑, PPARγ↑,
5817- CBD,    COX-2 and PPAR-γ confer cannabidiol-induced apoptosis of human lung cancer cells
- vitro+vivo, Lung, A549
AntiTum⇅, tumCV↓, Apoptosis↑, eff↓, COX2/PTGS2↑, PPARγ↑,
6217- CUR,    Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway
- Review, Var, NA
Wnt↓, β-catenin/ZEB1↓, PPARγ↑, Akt↓, *ROS↓, *Inflam↓, Bcl-2↓, GSK‐3β↑, NF-kB↓, COX2/PTGS2↓,
123- CUR,    Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells
- in-vitro, Colon, LoVo - in-vitro, Colon, COLO205 - in-vitro, Pca, PC3 - in-vitro, Pca, 22Rv1
NF-kB↓, ATF3↑, HO-1↑, Wnt↓, Akt↓, mTOR↓, PTEN↑, Apoptosis↑, TGF-β↓, PPARγ↑,
13- CUR,    Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action
- Review, BC, NA
P53↑, DR5↑, JNK↑, NRF2↑, PPARγ↑, HER2/EBBR2↓, IR↓, ER(estro)↓, Fas↑, PDGF↓, TGF-β↓, FGF↓, EGFR↓, JAK↓, PAK↓, MAPK↓, ATPase↓, COX2/PTGS2↓, MMPs↓, IL1↓, IL2↓, IL5↓, IL6↓, IL8↓, IL12↓, IL18↓, NF-kB↓, NOTCH1↓, STAT1↓, STAT4↓, STAT5↓, STAT3↓,
6342- DRE,    Mechanistic Study on the Inhibitory Effect of Dandelion Extract on Breast Cancer Cell Proliferation and Its Induction of Apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, Nor, MCF10
eff↑, selectivity↑, Apoptosis↑, TumCCA↑, PI3K↓, Akt↓, JAK1↓, STAT↓, PPARγ↑, TumCP↓, SIRT6↓, SCD1↓, STAT3↓, Casp8↓, STAT6↓, PAK1↓, FABP4↓,
7539- HT,    Polyphenols Extracts from Oil Production Waste Products (OPWPs) Reduce Cell Viability and Exert Anti-Inflammatory Activity via PPARγ Induction in Colorectal Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, LoVo
tumCV↓, Apoptosis↑, TumCCA↑, p‑NF-kB↑, TNF-α↑, IL8↓, PPARγ↑, Inflam↓, Dose↝,
7676- iod,    Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR)
- in-vivo, BC, NA
TumCP↓, Apoptosis↑, Dose↝, other↑, BloodF↓, VEGF↓, UroPA↓, PPARα↓, DR4↑, Casp3↑, PPARγ↑, antiNeop↑, Risk↓, 6IL↑,
7677- iod,    Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone
- in-vitro, BC, MCF7
TumCP↓, 6IL↑, PPARγ↑, AntiCan↑,
7679- iod,    Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin
- in-vivo, BC, MCF7
AntiTum↑, tumCV↓, Apoptosis↑, Bax:Bcl2↑, Bcl-2↓, MDR1↑, PPARγ↑, CD44↓,
7682- iod,    Molecular Iodine Induces Anti- and Pro-Neoplastic Effects in Prostate Cancer Models
- in-vitro, Pca, LNCaP - in-vitro, Pca, DU145 - in-vitro, Pca, PC3
PPARγ↑, antiNeop↑, TumCD↑, TumCI↓, AntiCan⇅, antiOx↑, Inflam↓, Apoptosis↑, tumCV↓,
7686- iod,    Molecular Iodine Exhibited Differential Antiproliferative Actions in Progenitor and Stem Populations from Chemoresistant Cancer Cells
- vitro+vivo, BC, MCF7
PPARγ↑, Apoptosis↑, Bax:Bcl2↑, CSCs↓, NRF2↑, tumCV↓, TumCI↓,
7687- iod,  ESWT,    Shock Wave Application Increases the Antineoplastic Effect of Molecular Iodine Supplement in Breast Cancer Xenografts
- in-vivo, BC, MDA-MB-231
antiNeop↑, CSCsMark↓, CD44↓, SOX2↓, HIF-1↓, VEGF↓, Dose↝, Dose↝, EPR↝, PPARγ↑,
7781- ISL,    Perspectives on the Role of Isoliquiritigenin in Cancer
- Review, Var, NA
*BioAv↝, *BBB↓, *BioAv↑, selectivity↑, *neuroP↑, *Inflam↓, NF-kB↓, TNF-α↓, IL6↓, IL1β↓, IL10↓, ICAM-1↓, COX2/PTGS2↓, PPARγ↑, MMP2↓, cFos↓, VEGF↓, CHOP/DDIT3↓, CTSK↓, CycB/CCNB1↑, cycD1/CCND1↑, TOP2↑, PI3K↓, Akt↓, mTOR↓, MMP9↓, TIMP1↓, ChemoSen↑, CSCs↓,
8198- LGE,    Citral, a component of lemongrass oil, activates PPARα and γ and suppresses COX-2 expression
- in-vitro, Var, NA
COX2/PTGS2↓, PPARα↑, PPARγ↑,
8325- LIN,    Validating linalool as a potential drug for breast cancer treatment based on machine learning and molecular docking
- in-vitro, BC, NA
tumCV↓, TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, TumCCA↑, PPARγ↑, PGK1↓,
3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
antiOx↑, TumCP↓, Apoptosis↑, TumMeta↑, ChemoSen↑, BioAv↓, Dose↝, BioAv↓, BioAv↑, SOD↑, Catalase↑, GPx↑, IL2↑, IL4↑, IL1↑, TNF-α↑, GSH↑, GPx↑, GSTA1↑, GSR↑, PPARγ↑, Casp3↑, NF-kB↓, COX2/PTGS2↓, Bcl-2↑, BAX↓, P53↓, CHK1↓, Chk2↓, γH2AX↓, DNAdam↓, ROS↓, P21↑, PCNA↓, β-catenin/ZEB1↓, PGE2↓, ERK↓, cMyc↓, cycE/CCNE↓, JAK1↓, STAT3↓, SIRT1↑, cl‑PARP↑, cycD1/CCND1↓, TNF-α↓, IL6↓, p65↓, MMP2↓, MMP9↓, Wnt↓,
1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
OS↑, ChemoSen↑, QoL↑, PSA∅, eff↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2/PTGS2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27/CDKN1B↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,
4791- Lyco,    Investigating into anti-cancer potential of lycopene: Molecular targets
- Review, Var, NA
*antiOx↑, TumCP↓, TumCCA↓, Apoptosis↑, TumCI↓, angioG↓, TumMeta↓, *Risk↓, cycD1/CCND1↓, CycD3↓, cycE/CCNE↓, CDK2↓, CDK4↓, Bcl-2↓, P21↑, p27/CDKN1B↑, P53↑, BAX↑, selectivity↑, MMP↓, Cyt‑c↑, Wnt↓, eff↑, PPARγ↑, LDL↓, Akt↓, PI3K↓, mTOR↓, PDGF↓, NF-kB↓, eff↑,
193- MFrot,  MF,    Rotating Magnetic Field Mitigates Ankylosing Spondylitis Targeting Osteocytes and Chondrocytes via Ameliorating Immune Dysfunctions
- in-vivo, Arthritis, NA
BMD↑, Cartilage↑, IL17↓, IL22↓, IL23↓, IL28↓, CD4+↓, CD8+↓, LAMB3↑, COL4↓, THBS2↓, ITGA11↓, PPARγ↑, ACAA1↓, PLIN1↓, FABP4↓, PCK1↓, UCP1↓, TNF-α↓,
4643- OLE,  HT,    Use of Oleuropein and Hydroxytyrosol for Cancer Prevention and Treatment: Considerations about How Bioavailability and Metabolism Impact Their Adoption in Clinical Routine
- Review, Var, NA
TumCCA↑, Apoptosis↑, ER Stress↑, UPR↑, CHOP/DDIT3↑, ROS↑, Bcl-2↓, NOX4↑, Hif1a↓, MMP2↓, MMP↓, VEGF↓, Akt↓, NF-kB↓, p65↓, SIRT3↓, mTOR↓, Catalase↓, SOD2↓, FASN↓, STAT3↓, HDAC2↓, HDAC3↓, BAD↑, BAX↑, Bak↑, Casp3↑, Casp9↑, PARP↑, P53↑, P21↑, p27/CDKN1B↑, Half-Life↝, BioAv↓, BioAv↓, selectivity↑, RadioS↑, *ROS↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *NRF2↑, *chemoP↑, *Inflam↓, PPARγ↑,
49- QC,    Plasma rich in quercetin metabolites induces G2/M arrest by upregulating PPAR-γ expression in human A549 lung cancer cells
- in-vitro, Lung, A549
CDK1↓, CycB/CCNB1↓, PPARγ↑,
3010- RosA,    Exploring the mechanism of rosmarinic acid in the treatment of lung adenocarcinoma based on bioinformatics methods and experimental validation
- in-vitro, Lung, A549 - in-vivo, NA, NA
TumCG↓, Ki-67↓, FABP4↑, PPARα↑, ROS↑, Apoptosis↑, MMP9↓, IGFBP3↓, MMP2↓, EMT↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, Gli1↓, PPARγ↑, Cyt‑c↑,
3426- TQ,    Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms
- in-vitro, BC, MDA-MB-468 - in-vitro, AML, JK
UHRF1↓, DNMT1↓, DNMT3A↓, DNMTs↓, HDAC1↓, HDAC4↓, HDAC↓, DLC1↑, PPARγ↑, FOXO↑, TET2↑, CYP1B1↑, G9a↓,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1/ATG6↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2/PTGS2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2/KDR/Flk1↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27/CDKN1B↑, P21↑, ChemoSen↑,
2124- TQ,    Thymoquinone: an emerging natural drug with a wide range of medical applications
- Review, Var, NA
hepatoP↑, Bax:Bcl2↑, cycD1/CCND1↓, P21↑, TRAIL↑, P53↑, TumCCA↑, hepatoP↑, *ALAT↓, *AST↓, *MDA↓, *GSSG↓, *COX2/PTGS2↓, *lipid-P↓, PPARγ↑, p38↑, ROS↑, ChemoSen↑, selectivity↑, selectivity↑, *MDA↓, *SOD↑,

Showing Research Papers: 1 to 30 of 30

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 30

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

6IL↑, 2,   CTSK↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   ATF3↑, 1,   Catalase↓, 1,   Catalase↑, 2,   GPx↑, 4,   GSH↑, 2,   GSR↑, 1,   GSTA1↑, 1,   HO-1↑, 2,   lipid-P↑, 1,   MDA↓, 1,   NOX4↑, 1,   NRF2↑, 3,   ROS↓, 1,   ROS↑, 5,   ROS⇅, 2,   SIRT3↓, 1,   SOD↑, 2,   SOD2↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 1,   MMP↓, 3,   MPT↑, 1,   UCP1↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACAA1↓, 1,   AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 2,   FABP4↓, 2,   FABP4↑, 1,   FASN↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 2,   IR↓, 1,   lactateProd↓, 1,   LDL↓, 1,   PCK1↓, 1,   PGK1↓, 1,   PKM2↓, 1,   PLIN1↓, 1,   PPARα↓, 1,   PPARα↑, 3,   PPARγ↑, 30,   SCD1↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 9,   p‑Akt↓, 1,   Apoptosis↑, 15,   BAD↑, 1,   Bak↑, 1,   BAX↓, 1,   BAX↑, 2,   Bax:Bcl2↑, 4,   Bcl-2↓, 7,   Bcl-2↑, 1,   BID↓, 1,   Casp↑, 1,   Casp3↑, 7,   Casp8↓, 1,   Casp8↑, 1,   Casp9↑, 2,   Chk2↓, 1,   Cyt‑c↑, 4,   DR4↑, 1,   DR5↑, 3,   FADD↑, 1,   Fas↑, 3,   iNOS↓, 2,   JNK↑, 3,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 2,   Myc↓, 1,   p27/CDKN1B↑, 4,   p38↓, 1,   p38↑, 3,   survivin↓, 1,   TRAIL↑, 2,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   PAK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,   tumCV↓, 6,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   CHOP/DDIT3↑, 1,   eIF2α↓, 1,   ER Stress↑, 2,   GRP78/BiP↑, 1,   HSP70/HSPA5↓, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 2,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1,   CYP1B1↑, 2,   DNAdam↓, 1,   DNAdam↑, 1,   DNMT1↓, 2,   DNMT3A↓, 1,   DNMTs↓, 1,   G9a↓, 1,   p16↑, 1,   P53↓, 1,   P53↑, 6,   PARP↑, 1,   cl‑PARP↑, 2,   PCNA↓, 2,   SIRT6↓, 1,   UHRF1↓, 2,   γH2AX↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↓, 4,   CDK4↓, 4,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 5,   cycD1/CCND1↑, 1,   CycD3↓, 1,   cycE/CCNE↓, 3,   E2Fs↓, 1,   P21↑, 6,   TumCCA↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD44↓, 2,   cFos↓, 1,   cMET↓, 1,   CSCs↓, 2,   CSCsMark↓, 1,   EMT↓, 2,   ERK↓, 2,   p‑ERK↓, 1,   FGF↓, 1,   FOXO↑, 2,   FOXO3↓, 1,   Gli1↓, 1,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   HDAC↓, 1,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   HH↓, 1,   IGF-1↓, 1,   IGFBP3↓, 1,   mTOR↓, 6,   p‑mTOR↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   P70S6K↓, 1,   PI3K↓, 6,   PTEN↑, 2,   SOX2↓, 1,   STAT↓, 1,   STAT1↓, 1,   STAT3↓, 7,   p‑STAT3↓, 1,   STAT4↓, 1,   STAT5↓, 1,   STAT6↓, 1,   TOP2↑, 1,   TumCG↓, 1,   Wnt↓, 5,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AP-1↓, 1,   ATPase↓, 1,   AXL↓, 1,   Ca+2↑, 1,   CAFs/TAFs↓, 1,   Cartilage↑, 1,   COL4↓, 1,   DLC1↑, 2,   ITGA11↓, 1,   ITGA5↓, 1,   Ki-67↓, 2,   LAMB3↑, 1,   MMP2↓, 7,   MMP7↓, 2,   MMP9↓, 8,   MMPs↓, 1,   N-cadherin↓, 1,   PAK1↓, 1,   PDGF↓, 2,   Slug↓, 2,   Snail?, 1,   Snail↓, 1,   TGF-β↓, 3,   THBS2↓, 1,   TIMP1↓, 1,   TumCI↓, 5,   TumCMig↓, 2,   TumCP↓, 8,   TumMeta↓, 2,   TumMeta↑, 1,   Twist↓, 3,   uPA↓, 1,   UroPA↓, 1,   Vim↓, 1,   Zeb1↓, 2,   ZEB2↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 3,   EGFR↓, 1,   EPR↝, 1,   HIF-1↓, 1,   Hif1a↓, 5,   NO↓, 1,   VEGF↓, 9,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↓, 1,   COX2/PTGS2↓, 10,   COX2/PTGS2↑, 1,   CRP↓, 1,   CXCL1↓, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL1↓, 2,   IL1↑, 1,   IL10↓, 2,   IL10↑, 1,   IL12↓, 2,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL2↓, 1,   IL2↑, 2,   IL22↓, 1,   IL23↓, 1,   IL28↓, 1,   IL4↓, 1,   IL4↑, 2,   IL5↓, 1,   IL6↓, 6,   IL8↓, 2,   Inflam↓, 2,   JAK↓, 1,   JAK1↓, 2,   JAK2↓, 2,   M2 MC↓, 1,   NF-kB↓, 10,   p‑NF-kB↑, 1,   p65↓, 3,   PGE2↓, 2,   PSA∅, 1,   TNF-α↓, 6,   TNF-α↑, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 2,   ER(estro)↓, 1,   GR↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 1,   ChemoSen↑, 6,   Dose↝, 5,   eff↓, 1,   eff↑, 10,   Half-Life↝, 1,   MDR1↑, 1,   RadioS↑, 2,   selectivity↑, 7,   TET2↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF↓, 1,   BMD↑, 1,   CRP↓, 1,   E6↓, 1,   E7↓, 1,   EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 6,   Ki-67↓, 2,   Myc↓, 1,   PSA∅, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiCan⇅, 1,   antiNeop↑, 3,   AntiTum↑, 1,   AntiTum⇅, 1,   hepatoP↑, 2,   OS↑, 1,   QoL↑, 1,   Risk↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↓, 1,  
Total Targets: 288

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GSH↑, 1,   GSSG↓, 1,   lipid-P↓, 1,   MDA↓, 3,   NRF2↑, 1,   ROS↓, 2,   SOD↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Inflam↓, 4,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1,   chemoP↑, 1,   neuroP↑, 1,   Risk↓, 1,  
Total Targets: 21

Scientific Paper Hit Count for: PPARγ, Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG)
6 iodine
3 Curcumin
3 Lycopene
3 Thymoquinone
2 HydroxyTyrosol
1 alpha Linolenic acid
1 Artemisinin
1 Baicalein
1 Beta-Caryophyllene
1 Carvacrol
1 Cannabidiol
1 Dandelion Root
1 Extracorporeal Shock Wave Therapy
1 Isoliquiritigenin
1 Lemongrass Extract/Citral
1 Linalool
1 Magnetic Field Rotating
1 Magnetic Fields
1 Oleuropein
1 Quercetin
1 Rosmarinic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:259  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page